SecBot SecBot

INBX drug pipeline

Inhibrx Biosciences, Inc. · 2 rated drugs
$77.66
−6.8% 1-day · Nov 16
Next catalyst
Apr 14, 2027
ozekibart PDUFA date · in 148 days
Typical move on FDA news
±3.1%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
2
2 bullish
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Apr 14, 2027148d
    ozekibart
    PDUFA date · unresectable or metastatic conventional chondrosarcoma

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/PDUFA (BLA accepted by FDA)
Time to marketPDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.

ozekibart Updated Nov 13

148days
Next catalyst
PDUFA date · Apr 14, 2027 · unresectable or metastatic conventional chondrosarcoma
What to watch

The next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.

Bull case
  • Registrational trial showed ozekibart reduced the risk of disease progression or death by 52% vs placebo, a clinically meaningful result in a setting with no approved therapies.
  • BLA was accepted by FDA with no filing review issues identified, and a PDUFA date is set for April14,2027 -- a clear binary catalyst within ~5 months.
  • If approved, ozekibart would be the first and only FDA-approved systemic treatment for unresectable or metastatic conventional chondrosarcoma, a clear orphan-drug market.
Bear case
  • Inhibrx has $199.5M cash vs $275M in debt and a $38.7M quarterly burn, requiring the newly filed $150M ATM (filed Nov13,2026) that dilutes existing shareholders.
  • Short interest is ~23% of shares outstanding as of October30,2026, with 10 days to cover -- a heavy bearish bet against approval or commercial success.
  • No FDA-approved systemic therapy currently exists for chondrosarcoma, and the FDA could still issue a Complete Response Letter despite positive data.
▲ bullish
Impact
PhasePhase 2 (Phase 2/3 HexAgon-HN study)
Time to marketIf the Phase 2 expansion data supports accelerated approval discussions, a BLA filing could follow in 2027-2028, with potential approval in 2028-2029 for HNSCC. The Phase 3 portion of the HexAgon-HN study is already ongoing.

ordastobart Updated Nov 16

What to watch

Watch for the Phase 2 expansion readout in HNSCC expected mid-2027, which will show whether the strong Phase 2 interim data (48.3% cORR, 9.6-month PFS) holds in a larger cohort. Positive data could support accelerated approval discussions; negative data would undercut the pipeline thesis. Also monitor the ozekibart PDUFA date of April 14, 2027, which is the company's nearer-term binary catalyst.

Bull case
  • First OX40 agonist to demonstrate clinical benefit in a randomized study, nearly doubling response rate (48.3% vs 26.5%) and showing 9.6-month median PFS vs pembrolizumab alone in first-line HNSCC.
  • CEO Mark Lappe has been consistently buying shares on the open market in Sept-Oct 2026, investing over $1.8M at prices around $84-$102, signaling insider confidence.
  • Analyst consensus is strongly bullish: 8 Buy/Strong Buy vs 2 Hold, with a mean price target of $266.67 implying ~220% upside from the $83.30 close.
Bear case
  • OX40 agonist drug class has a history of clinical failures; INBRX-106 is the first to show positive randomized data but the sample is still small and durability unproven.
  • Phase 2 expansion and NSCLC readouts are not expected until mid-2027, leaving a long period with no near-term binary catalyst for this specific drug.
  • Inhibrx has $276.7M in long-term debt against $199.5M cash, burning ~$39M/quarter, creating potential dilution risk before any commercial revenue.

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Oct 1, 2026ozekibartAccelerated approval−3.1%−7.3%
Jun 30, 2026ozekibartBLA filed−0.6%+1.7%
Jun 15, 2026ozekibartBLA filed+1.0%+0.8%
Jun 1, 2026ozekibartBLA filed−10.0%−14.3%
Apr 30, 2026ozekibartBLA filed+3.2%−0.2%
Apr 1, 2026ozekibartBLA filed−5.5%+12.7%